EVFM
Evofem Biosciences, Inc.0.0100
-0.0010-9.09%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
1.27MP/E (TTM)
-Basic EPS (TTM)
-0.05Dividend Yield
0%Recent Filings
8-K
Reverse split authorized
Evofem stockholders approved a Certificate of Incorporation amendment on November 26, 2025, authorizing a one-time reverse stock split of common stock at a 1-for-500 to 1-for-1,500 ratio, exercisable by the Board before November 26, 2026. Voters also elected four directors to 2028 terms, ratified the 2025 Equity Incentive Plan, approved say-on-pay, and confirmed BPM LLP as auditors. Total authorized shares unchanged. Split awaits Board action.
8-K
Q3 profit amid cost cuts
Evofem Biosciences posted Q3 net sales of $5.0 million, up 10% from $4.5 million last year, while slashing operating expenses 42% to deliver $1.0 million operating income. Manufacturing costs for PHEXX and SOLOSEC dropped ~50%, aiding global expansion after UAE submission. Merger with Aditxt terminated. Cash remains tight at $0.8 million restricted.
10-Q
Q3 FY2025 results
Evofem posted Q3 revenue of $5.0M, up 10% y/y from $4.5M yet down q/q (derived), fueled by full-quarter SOLOSEC sales after its July 2024 acquisition and higher PHEXX pricing; operating income swung to $1.0M from a $2.4M loss, thanks to a $1.9M gain reversing unowed Rush royalties. Gross margins strengthened sans royalties, while expenses held steady. Cash sits at zero with $0.8M restricted; debt tops $160M amid Baker Notes default claims. Receivables collections improved liquidity. Customer concentration lingers.
8-K
Merger terminated by shareholder vote
Evofem Biosciences terminated its merger agreement with Aditxt on October 20, 2025, after shareholders rejected the deal at a special meeting, with 93.2 million votes for but 7.2 million against among 100.5 million cast. No termination fees were paid, ending ancillary pacts except a 2023 NDA. The company now pivots to regaining national stock listing and raising growth capital to hit positive EBITDA in 2027. Merger fallout risks litigation and partner retention.
BSEM
BioStem Technologies, Inc.
3.84-0.11
CASI
CASI Pharmaceuticals, Inc.
0.88+0.01
DARE
Dare Bioscience, Inc.
2.26-0.02
ENDV
Endonovo Therapeutics, Inc.
0.00+0.00
ENVB
Enveric Biosciences, Inc.
5.24-0.12
EPIX
ESSA Pharma Inc.
0.20+0.00
EVGN
Evogene Ltd.
1.04+0.00
EVOK
Evoke Pharma, Inc.
11.00+0.04
FEMY
Femasys Inc.
0.85-0.01
PHGE
BiomX Inc.
1.55-0.18